Juliet is a biopharma leader with experience in clinical development, business development, portfolio strategy, finance, marketing, and sales. She has worked in venture backed start-ups and global pharmaceutical companies. At AstraZeneca, she led the launch of Imfinzi in lung cancer, which achieved blockbuster status the fastest of any AZ product. Prior to AZ she worked at Bristol-Myers Squibb, where she led the marketing team for Erbitux in head & neck cancer, and was the global commercial lead for lung portfolio strategy, providing commercial input for early oncology clinical development programs. Prior to BMS, Juliet worked at EMD Serono, where she was a member of global product teams overseeing development of early and late-stage oncology molecules. She began her oncology work at Genentech, where she worked on the Avastin clinical development team. Juliet started her biopharma career at Eyetech Pharmaceuticals, a venture backed start-up which went public and was acquired by OSI. There she focused on finance and business development, working on the Pfizer Macugen deal, the 3rd largest biotech licensing agreement at the time, and in-licensing ophthalmology candidates. Juliet has an MBA from Columbia Business School and a BA from Bryn Mawr College.
